Faribourz Payvandi, PhD
Founder and CEO

Dr. Payvandi has more than 30 years of experience in the clinical development of novel products including small chemical compounds, monoclonal antibodies, recombination proteins and therapeutic cellular products such as stem cells. He received his M.S. in Immunology from the University of Lincoln, Nebraska, and his PhD in Immunology from the University of Medicine and Dentistry, New Jersey. He did his post-doctoral training in the field of oncology/immunology of prostate cancer. He then joined Schering Plough (now Merck), where he spearheaded hybridoma technology use in producing monoclonal antibodies against various cytokines involved in inflammatory processes. Then, at Celgene, he was instrumental in the groundbreaking research involving thalidomide and its analogues for the treatment of hematopoietic tumors. Specifically, he was involved in the development and FDA approval of Lenalidomide, which became a multi-billion dollar drug for the company. His laboratory developed an in vivo model of angiogenesis using umbilical cords. This model has since been patented and used for anti-angiogenic activity of cancer drugs. Over the last decade, his research interests expanded to include stem cell therapy. He was CEO and Founder of Neolomed Biosciences where he characterized stem cells for therapeutic purposes. And most recently served as CSO of 3D Biotek, where he led R&D for expansion and characterization of stem cells.

​
Naheed Banu, PhD
Director of Pre-Clinical Development
Sudabeh Pakray, MS
Director of QC and QA
Mike Ameri
Mechanical Engineer
Al Parotta
Regulatory Consultant
Kevin Brett, CPA
Accountant and Finance